A23L33/115

FORMULATIONS AND USES THEREOF
20230000987 · 2023-01-05 ·

Preparations and formulations capable of crossing and incorporating into a membrane of a cell or an organelle or an exosome are described. Methods of treatments utilizing the preparations and formulations are also described.

Protective effects of oil palm composition on Alzheimer's disease

Present invention discloses an oil palm composition for use in prevention or treatment of Alzheimer's disease. The composition is useful in impeding formation of neurotoxic peptide. Present invention can be used in preparation of a medicament in a therapeutic effective amount for prevention or treatment of Alzheimer's disease and diseases related thereto.

Protective effects of oil palm composition on Alzheimer's disease

Present invention discloses an oil palm composition for use in prevention or treatment of Alzheimer's disease. The composition is useful in impeding formation of neurotoxic peptide. Present invention can be used in preparation of a medicament in a therapeutic effective amount for prevention or treatment of Alzheimer's disease and diseases related thereto.

Method for the preparation of a monoglyceride hydrate product

The present invention relates to a method for preparing a monoglyceride hydrate product, which product may be used as an emulsifier in various food and non-food applications. The present invention further relates to the monoglyceride hydrate product obtainable by said method. The invention further relates to a monoglyceride hydrate product, comprising monoglycerides, with saturated fatty acid residues, water and non-hydrogenated monoglycerides and/or diglycerides having unsaturated fatty acid residues.

Method for the preparation of a monoglyceride hydrate product

The present invention relates to a method for preparing a monoglyceride hydrate product, which product may be used as an emulsifier in various food and non-food applications. The present invention further relates to the monoglyceride hydrate product obtainable by said method. The invention further relates to a monoglyceride hydrate product, comprising monoglycerides, with saturated fatty acid residues, water and non-hydrogenated monoglycerides and/or diglycerides having unsaturated fatty acid residues.

DIETARY BUTYRATE
20230024274 · 2023-01-26 ·

A nutritional composition for providing a source of butyrate or butyric acid comprising a compound having the formula (1) wherein R.sup.6 is along chain fatty acid having between 16 and 20 carbons.

##STR00001##

INFANT FORMULA
20230026618 · 2023-01-26 ·

An infant formula for use in preventing or reducing the occurrence of allergic sensitisation in an infant, wherein the infant formula comprises 0.8-2.5 g/L 2′-fucosyllactose (2′FL) and/or 0.05-0.2 g/L lacto-N-neotetraose (LNnT).

INFANT FORMULA
20230026618 · 2023-01-26 ·

An infant formula for use in preventing or reducing the occurrence of allergic sensitisation in an infant, wherein the infant formula comprises 0.8-2.5 g/L 2′-fucosyllactose (2′FL) and/or 0.05-0.2 g/L lacto-N-neotetraose (LNnT).

MIXTURE COMPRISING HYDROGENATED SOYBEAN OIL AND THYMOL
20230025537 · 2023-01-26 ·

The present invention relates to use of preferably fully hydrogenated soybean oil for manufacturing a particulate feed additive that is resistant to heat induced caking The mixture of the invention comprises hydrogenated soybean oil and thymol, wherein the weight ratio between hydrogenated soybean oil and thymol is from 10:1 to 1:1 and/or wherein the mixture comprises 5-30 weight-% of thymol, based on the total weight of the mixture. Preferably, the mixture is shaped as particles by spray chilling. The particles are then used as a feed additive. The feed additive may be a premix.

Production of aspirin-triggered resolvins without the use of aspirin in a dietary omega-3 supplement

The present invention includes a composition and method of producing aspirin in situ, the method comprising: identifying a subject in need of aspirin or aspirin-like compounds; and providing the subject with a composition comprising: a source of methyl salicylate, an acetyl donor, and L-Arginine, wherein the composition is effective to produce aspirin-triggered resolvins in the subject without the deleterious effect of the aspirin or aspirin-like compounds in the stomach.